Regeneron Pharmaceuticals (REGN) Deferred Taxes (2013 - 2026)

Regeneron Pharmaceuticals' Deferred Taxes history runs 14 years deep, the most recent figure standing at $96.0 million for Q1 2026.

• In Q1 2026, Deferred Taxes fell 30.98% year-over-year to $96.0 million; the TTM figure through Mar 2026 stood at $742.3 million (up 5.14% YoY), while the FY2025 annual figure was $785.4 million, up 3.71% from the prior year.
• Deferred Taxes was $96.0 million for Q1 2026 at Regeneron Pharmaceuticals, down from $232.5 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $286.3 million in Q4 2023 to a low of $85.7 million in Q3 2022.
• Historically, Deferred Taxes has averaged $189.6 million across 5 years, with a median of $190.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Deferred Taxes surged 2327.72% in 2022, then tumbled 43.57% in 2024.
• A 5-year view of Deferred Taxes shows it stood at $279.7 million in 2022, then climbed by 2.36% to $286.3 million in 2023, then retreated by 2.13% to $280.2 million in 2024, then declined by 17.02% to $232.5 million in 2025, then plunged by 58.71% to $96.0 million in 2026.
• The last three Deferred Taxes figures came in at $96.0 million (Q1 2026), $232.5 million (Q4 2025), and $278.6 million (Q3 2025), per Business Quant data.